Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ODAC Sides With FDA: Evidence For Elderly AML Drugs Can't Stand On Single-Arm Trials

This article was originally published in The Pink Sheet Daily

Executive Summary

Feasible or not, randomized controlled trials are needed before approval of Genzyme's Clolar and Vion's Onrigin to treat elderly acute myeloid leukemia patients.
Advertisement

Related Content

Eisai Will Make “Totality Of The Evidence” Argument At FDA Panel Review Of Dacogen
Cell Therapeutics Boosts Late-Stage Pipeline With Chroma's Tosedostat
Cell Therapeutics Boosts Late-Stage Pipeline With Chroma's Tosedostat
Vion's Fate Depends On Raising Funds To Conduct New Onrigin Study
No Regulatory Slack For Tough Supplemental Indications, Pazdur Tells ODAC
ODAC's Vote For Another Trial Could Be Death Knell For Vion's Onrigin
Allos' Folotyn and Gloucster's Istodax: Exceptions That Prove The Rule?
Day Two At ODAC: Reviewing Drugs To Treat T-Cell Lymphoma In A Difficult Class
Day Two At ODAC: Reviewing Drugs To Treat T-Cell Lymphoma In A Difficult Class
Can Tricky Elderly AML Population Justify Weak Data? Fate Of Genzyme's Clolar and Vion's Onrigin Rests With ODAC

Topics

Advertisement
UsernamePublicRestriction

Register

PS069947

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel